EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers

Tamara Schejter-Margalit iD, Noam Ben Binyamin, Avner Thaler, Inbal Maidan iD, Jesse M Cedarbaum, Avi Orr-Urtreger, Mali Gana Weisz, Orly Goldstein, Nir Giladi iD, Anat Mirelman, Rachel Kizony

European Journal of Neurology · 2024

DOI: 10.1111/ene.16327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Tamara Schejter-Margalit und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Early Markers of Neurodegeneration, Center for the Study of Movement, Cognition, and Mobility, Tel Aviv Sourasky Medical Center, Tel A…. Hauptthemen laut MEDLINE: Parkinson Disease, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Glucosylceramidase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Subtle executive dysfunction is common in people newly diagnosed with Parkinson disease (PD), even when general cognitive abilities are intact. This study examined the Short Weekly Calendar Planning Activity (WCPA‐10)'s known‐group construct validity, comparing persons with PD to healthy controls (HCs) and nonmanifesting carriers of LRRK2 and GBA gene mutations to HCs. Additionally, convergent and ecological validity was examined.

Methods

The study included 73 participants: 22 with idiopathic PD (iPD) who do not carry any of the founder GBA mutations or LRRK2 ‐G2019S, 29 nonmanifesting carriers of the G2019S‐ LRRK2 ( n = 14) and GBA ( n = 15) mutations, and 22 HCs. Known‐group validity was determined using the WCPA‐10, convergent validity by also using the Montreal Cognitive Assessment (MoCA) and Color Trails Test (CTT), and ecological validity by using the WCPA‐10, Schwab and England Activities of Daily Living Scale (SE ADL), and Physical Activity Scale for the Elderly (PASE).

Results

Known‐group validity of the WCPA‐10 was established for the iPD group only; they followed fewer rules ( p = 0.020), were slower ( p = 0.003) and less efficient ( p = 0.001), used more strategies ( p = 0.017) on the WCPA‐10, and achieved significantly lower CTT scores ( p < 0.001) than the HCs. The nonmanifesting carriers and HCs were similar on all cognitive tests. Convergent and ecological validity of the WCPA‐10 were partially established, with few correlations between WCPA‐10 outcome measures and the MoCA ( r = 0.50, r = 0.41), CTT‐2 ( r = 0.43), SE ADL ( r = 0.41), and PASE ( r = 0.54, r = 0.46, r = 0.31).

Conclusions

This study affirms the known‐group validity for most (four) WCPA‐10 scores and partially confirms its convergent and ecological validity for PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLeucine-Rich Repeat Serine-Threonine Protein Kinase-2GlucosylceramidaseHumansFemaleMaleMiddle AgedAgedExecutive FunctionHeterozygoteActivities of Daily LivingReproducibility of ResultsMutationNeuropsychological Tests

Stichwörter der Autor:innen

GBALRRK2Parkinson diseasecognitionecologically valid tool

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2GlucosylceramidaseLRRK2 protein, humanGBA protein, human

Autor:innen und Institutionen

  • Laboratory for Early Markers of Neurodegeneration, Center for the Study of Movement, Cognition, and Mobility, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Occupational Therapy Department, University of Haifa, Haifa, Israel.
  • Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
  • Yale University School of Medicine and Coeruleus Clinical Sciences, Woodbridge, Connecticut, USA.
  • Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Occupational Therapy, Sheba Medical Center, Tel Hashomer, Israel.

ORCID-Profile: Tamara Schejter-Margalit, Inbal Maidan, Nir Giladi

Förderung

  • NCATS NIH HHS
  • Biogen

Zitieren

APA

Schejter-Margalit, T., Binyamin, N. B., Thaler, A., Maidan, I., Cedarbaum, J. M., Orr-Urtreger, A., Gana Weisz, M., Goldstein, O., Giladi, N., Mirelman, A., & Kizony, R. (2024). Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers. European Journal of Neurology. https://doi.org/10.1111/ene.16327

Vancouver

Schejter-Margalit T, Binyamin NB, Thaler A, Maidan I, Cedarbaum JM, Orr-Urtreger A, et al. Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers. European Journal of Neurology. 2024. doi:10.1111/ene.16327

BibTeX
@article{SchejterMargalit2024,
  author = {Schejter-Margalit, Tamara and Binyamin, Noam Ben and Thaler, Avner and Maidan, Inbal and Cedarbaum, Jesse M and Orr-Urtreger, Avi and Gana Weisz, Mali and Goldstein, Orly and Giladi, Nir and Mirelman, Anat and Kizony, Rachel},
  title = {Validity of the Short Weekly Calendar Planning Activity in patients with Parkinson disease and nonmanifesting LRRK2 and GBA carriers},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16327}
}
Kostenlos starten →